Issue 106 • May 2021

Human challenge trials

Drug dispensing goes digital

The future of regenerative medicine

Antibiotic Adjacent 

With the threat of antimicrobial resistance looming, researchers are exploring alternative treatment options

In association with

02/23/2024 22:36:39
  • Home | Antibiotic Adjacent
  • In this issue
  • Contents
  • SHL Company Insight
  • SHL Medical
  • Tive
  • Controlant Company Insight
  • Controlant
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Mimotopes Company Insight
  • Mimotopes
  • L.B. Bohle Maschinen
  • L.B Bohle Company Insight
  • ACG Worldwide
  • Comment
  • HPV infections drop due to widespread vaccination
  • Europe reports the highest prevalence of chronic cough across the 7MM
  • How could vaccine hesitancy affect the prevalence of hearing disorders?
  • Datwyler Company Insight
  • Datwyler
  • RegPak
  • Pfeiffer
  • In Depth
  • Antibiotic adjacent: the alternatives tackling AMR
  • Regenerative medicine: ready for the big leagues?
  • Human challenge trials: pandemic exit strategy or ethical nightmare?
  • Drug dispensing goes digital
  • Could this Novartis initiative finally cure sickle cell disease?
  • Centessa Pharmaceuticals: forging a new path for pharma R&D
  • Biomax Company Insight
  • Biomax
  • Duoject
  • Duoject Company Insight
  • In Data
  • Deals analysis
  • The pharma industry key list
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • The Solubility Company - Company Insight
  • The Solubility company
  • Myonex
  • Baxter
  • Events
  • Next issue
04/22/2021 00:00:00